Dana

Feinstein Institutes’ Dr. Kevin J. Tracey receives 2023 Hans Wigzell Research Foundation's Science Prize

Retrieved on: 
Thursday, November 2, 2023
Science, Health, Neurology, Research, Sequence, Feinstein Institutes for Medical Research, Inflammation, Karolinska Institute, Doctor of Philosophy, Rheumatoid arthritis, Biomedical sciences, Shock, Immunity, Neuroscience, Boston University, Neurosurgery, Death, Rockefeller University, Medical research, Hope, Nobel Committee, Vagus nerve stimulation, Reflex, Cytokine, Boston College, Royal Academies for Science and the Arts of Belgium, Northwell Health, Medicine, Credit, UNESCO Science Prize, Patient, Vagus nerve, Septic shock, Human, University Medical Center, BS, Laboratory, Travel, Olivia Wigzell, Chemistry, Survival, Education, Royal Academy of Arts, Water, Multimedia, Dana, Engineering, Rockefeller, Student, Dana Foundation, Sepsis, Inflammatory bowel disease, Nursing, Pharmaceutical industry, Medical device, MD

The Hans Wigzell Research Foundation today announced that Kevin J. Tracey, MD, president and CEO of Northwell Health’s Feinstein Institutes for Medical Research , is the recipient of the 2023 Hans Wigzell Research Foundation’s Science Prize in recognition of his significant contributions to the fields of neuroscience and neuroimmunology.

Key Points: 
  • The Hans Wigzell Research Foundation today announced that Kevin J. Tracey, MD, president and CEO of Northwell Health’s Feinstein Institutes for Medical Research , is the recipient of the 2023 Hans Wigzell Research Foundation’s Science Prize in recognition of his significant contributions to the fields of neuroscience and neuroimmunology.
  • Dr. Tracey will travel to Stockholm, Sweden, to receive the prize, which includes $100,000, and deliver a lecture on December 1.
  • View the full release here: https://www.businesswire.com/news/home/20231102553265/en/
    Dr. Kevin J. Tracey has been named awardee of the 2023 Hans Wigzell Research Foundation's Science Prize.
  • “The prize is given to Dr. Tracey for his innovative discoveries of the mechanisms of how nerves transmit signals to stop inflammatory diseases,” said Hans Wigzell, MD, PhD, on behalf of the Hans Wigzell Research Foundation.

Oncoclínicas opens first Cancer Center in Brazil as an International Collaborative Member of Dana-Farber Cancer Institute

Retrieved on: 
Wednesday, November 1, 2023
Gibbs Cancer Center & Research Institute, Harvard Medical School, Patient, Dana–Farber Cancer Institute, MD, Oncology, Organization, Hematological Cancer Research Investment and Education Act, Health, International Collaboration for the Care of the Elderly, Instituto Nacional de Medicina Genómica, Dana, Disease, Medicine, INCA, Partnership, Instituto Oncológico Nacional, Ferrari, Cancer, Pharmacist, Nursing, Patient safety, Pharmaceutical industry

The estimated investment by Oncoclinicas in the new Cancer Center is BRL 93 million, including infrastructure, technology, and operations.

Key Points: 
  • The estimated investment by Oncoclinicas in the new Cancer Center is BRL 93 million, including infrastructure, technology, and operations.
  • These facilities will be expanded to accommodate the new Oncoclínicas Cancer Center in Belo Horizonte e Nova Lima, an International Collaborative Member of Dana-Farber Cancer Institute.
  • "The Oncoclínicas cancer center in Belo Horizonte is the first outside the United States to receive the designation of international collaborating member of the Dana Farber Cancer Institute.
  • "Among other collaborative efforts, our multidisciplinary discussions contribute to democratizing cancer care for every patient across our operations in Brazil.

Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Hospitals, Other Health, National Academy of Medicine, Acute myeloid leukemia, Doctor of Philosophy, Memorial Sloan Kettering Cancer Center, Research, Francis Crick Institute, Bristol Myers Squibb, Harvard University, NAM, The Emperor of All Maladies, Cell biology, Medicine, National academy, Pulitzer Prize, Therapy, Immunotherapy, Genetics, Mukherjee, Assistant, Dana–Farber Cancer Institute, ARD International Music Competition, CRUK, Disease, Dana, National Academy of Science and Technology, Tony Faeth, Pharmaceutical industry

Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).

Key Points: 
  • Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).
  • "Dr. Mukherjee's induction into the National Academy of Medicine reaffirms Faeth Therapeutics' dedication to unparalleled scientific rigor and innovation.
  • In the National Academy of Medicine, members are elected by their colleagues as a testament to their exceptional accomplishments.
  • Being inducted into the academy represents one of the most prestigious accolades within the realm of medicine.

Dana Incorporated to Announce 2023 Third-quarter Financial Results, Host Conference Call and Webcast on Oct. 27

Retrieved on: 
Thursday, October 12, 2023
NYSE, Dana, Webcast, Telephone, EDT

MAUMEE, Ohio, Oct. 12, 2023 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) will release its 2023 third-quarter financial results on Friday, Oct. 27, 2023.

Key Points: 
  • MAUMEE, Ohio, Oct. 12, 2023 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) will release its 2023 third-quarter financial results on Friday, Oct. 27, 2023.
  • A press release will be issued at approximately 7 a.m. EDT, followed by a conference call and webcast at 9 a.m. EDT.
  • Members of the company's senior management team will be available at that time to discuss the results and answer related questions.
  • A webcast replay can be accessed via Dana's investor website following the call.

Flagler Technologies Expands to The Carolinas Bringing Seamless Technology Integration to Businesses of All Sizes

Retrieved on: 
Thursday, October 5, 2023
Knowledge, New Hire Registry, Dell, Flagler, Fortune 500, Health, Education, University, Entertainment, Dana–Farber Cancer Institute, Dana, University of Massachusetts Amherst

CHARLESTON, S.C., Oct. 5, 2023 /PRNewswire/ -- Flagler Technologies continues its southern United States expansion with the addition of Matt Maypother.

Key Points: 
  • CHARLESTON, S.C., Oct. 5, 2023 /PRNewswire/ -- Flagler Technologies continues its southern United States expansion with the addition of Matt Maypother.
  • Maypother is well versed in the technology world and has proven successful in his many sales roles over the last five years.
  • He has achieved many notable honors, including the New Hire MVP Award and the Fireside Award from Dell.
  • For more information about this appointment, or Flagler Technologies expansion, please visit flagler.io or call (561) 229-1601.

Dana Electrified Driveline Honored as Top New Power Technology at 2023 Diesel Progress Summit

Retrieved on: 
Thursday, September 28, 2023
Maintenance, Aerospace Journalist of the Year Awards, Noise, Agriculture, Forestry, Drivetrain, Transition, Mining, NYSE, Motion system, Dana, Film industry, Rail transport

MAUMEE, Ohio, Sept. 28, 2023 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) announced today that it has earned the New Power Technology Award for its e-Driveline and e-Motion drivetrain solution at 2023 Diesel Progress Summit this week.

Key Points: 
  • MAUMEE, Ohio, Sept. 28, 2023 /PRNewswire/ -- Dana Incorporated (NYSE: DAN) announced today that it has earned the New Power Technology Award for its e-Driveline and e-Motion drivetrain solution at 2023 Diesel Progress Summit this week.
  • Dana's fully-electrified driveline for compact construction vehicles helps original equipment manufacturers enhance the sustainability of their applications while improving energy efficiency and performance.
  • Dana won the Drivetrain Component of the Year Award for its Spicer® TE50 powershift transmission at the 2020 Diesel Progress Summit.
  • The company won two awards in 2021: the New Power Technology Award and the Achievement of the Year Award for its Spicer® Electrified e-Powertrain.

Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer

Retrieved on: 
Wednesday, September 27, 2023
Oncology, Medical Devices, Health, Health Technology, Research, Science, Genomic Health, University, Brigham and Women's Hospital, Duke University School of Medicine, Cancer, Multimedia, Medicine, Dartmouth College, Dana–Farber Cancer Institute, Reagan-Udall Foundation, Patient, Physician, Mortality, Hospital, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Microbiology, Dana, Nursing, Pharmaceutical industry, Illumina, Biology

Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.
  • He will report to Marc Stapley, Veracyte’s chief executive officer.
  • View the full release here: https://www.businesswire.com/news/home/20230927846710/en/
    Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Photo: Business Wire)
    “Phil is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley.
  • He most recently served as chief medical officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers.

Mellie Appoints Five New Industry Leaders to its Advisory Board

Retrieved on: 
Thursday, September 21, 2023
EBay, Boston Consulting Group, Insurance, National Alliance, Health, Marketing, GM, AARP, Parent, Health care, DoorDash, Cancer, Research, B2C, Advisory board, Dana–Farber Cancer Institute, SR, PHD, Jet.com, Blue Shield, Patient, SAN, Knowledge, Growth, Skai, Socialization, Transport, Caregiver, Dana, Wayfair, UnitedHealth Group, Autoimmunity, Product strategy, Pharmaceutical industry, Management, Innovation, Medicare, E-commerce

SAN FRANCISCO, Sept. 21, 2023 /PRNewswire/ -- Mellie, an award-winning elder care navigation solution for family caregivers, announced today the addition of five healthcare industry and business leaders to its Advisory Board, bolstering the company's access to expertise as it continues its momentum and growth.

Key Points: 
  • SAN FRANCISCO, Sept. 21, 2023 /PRNewswire/ -- Mellie, an award-winning elder care navigation solution for family caregivers, announced today the addition of five healthcare industry and business leaders to its Advisory Board, bolstering the company's access to expertise as it continues its momentum and growth.
  • The new members are:
    Deborah Fine, Chief Business Officer and Board Director, Mymee, previously Chief Corporate Affairs Officer, miR Scientific and President, Global Impact, Impact NRS.
  • I am thrilled to be joining their team of advisors to help the millions of people who need a resource like Mellie."
  • Micah Moreau is an expert in building marketplaces, bringing over 20 years of experience in ecommerce and marketing to Mellie.

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

Retrieved on: 
Thursday, September 7, 2023
Clinical Science (journal), Pediatrics, Cytomegalovirus, Q&A, HIV, Neoplasm, Brigham and Women's Hospital, Research, Weill Cornell Medical Center, Immunotherapy, Associate, Department of Medicine – University of Pamplona, Dana–Farber Cancer Institute, Harvard Medical School, Science, Weill Cornell Medicine, Patient, Melanoma, Viral, Webcast, Hospital, Dana, Vaccine

LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14th beginning at 4:00 p.m. Eastern time. Details about speakers and instructions on how to participate are below.

Key Points: 
  • LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14th beginning at 4:00 p.m. Eastern time.
  • She is also Nancy C. Paduano Professor and Chair, Weill Cornell Medicine.
  • The virtual program will be held online beginning at 4:00 p.m. Eastern Time and is expected to last approximately 90 minutes.
  • Following management’s presentations, a Q&A session will be available via the chat function of the webcast.

Rosemary Mazanet, M.D., PhD. Joins Columbia Care's Board of Directors

Retrieved on: 
Monday, September 11, 2023
Natural Resources, Alternative Medicine, Other Manufacturing, Health, Specialty, Cannabis, Manufacturing, Retail, Columbia University, University of Southern California, Heart, Database, University, Palliative care, Wharton School of the University of Pennsylvania, Journal of Palliative Medicine, Coronavirus Scientific Advisory Board, General partnership, Human, FSE, National Institutes of Health, Bangladesh Technical Education Board, Dana–Farber Cancer Institute, Harvard Medical School, Tablet, Leonard Davis Institute of Health Economics, Journal, RAND Corporation, Clinical research, Internal medicine, Filgrastim, Knowledge, Hospital, FDA, Dana, NEO, NLRB v. Kentucky River Community Care, Inc., Chair, JAMA, Pharmaceutical industry, Management, Amgen, New York University, Brigham

Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015.

Key Points: 
  • Dr. Mazanet began advising Columbia Care in 2013 and then joined its Scientific Advisory Board as its Chair in 2015.
  • Since 2013, she has played an integral role of developing groundbreaking form factors specifically for palliative care, such as pressed tablets.
  • I know she will continue to add significant value as a member of our Board of Directors.
  • Congratulations, Rosemary and thank you," said Nicholas Vita, CEO, Columbia Care.